These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 14670326

  • 1. Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection.
    Chen X, Li M, Le X, Ma W, Zhou B.
    Vaccine; 2004 Jan 02; 22(3-4):439-46. PubMed ID: 14670326
    [Abstract] [Full Text] [Related]

  • 2. Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus.
    Yang HJ, Chen M, Cheng T, He SZ, Li SW, Guan BQ, Zhu ZH, Gu Y, Zhang J, Xia NS.
    World J Gastroenterol; 2005 Jan 28; 11(4):492-7. PubMed ID: 15641132
    [Abstract] [Full Text] [Related]

  • 3. Immune responses to recombinant Mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice.
    Yue Q, Hu X, Yin W, Xu X, Wei S, Lei Y, Lü X, Yang J, Su M, Xu Z, Hao X.
    J Virol Methods; 2007 Apr 28; 141(1):41-8. PubMed ID: 17197041
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Recombinant heat shock protein 65 carrying hepatitis B core antigen induces HBcAg-specific CTL response.
    Yang BF, Zhao HL, Xue C, Xiong XH, Zhang W, Yao XQ, Liu ZM.
    Vaccine; 2007 May 30; 25(22):4478-86. PubMed ID: 17467856
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity of recombinant hepatitis B virus surface antigen fused with preS1 epitopes expressed in rice seeds.
    Qian B, Shen H, Liang W, Guo X, Zhang C, Wang Y, Li G, Wu A, Cao K, Zhang D.
    Transgenic Res; 2008 Aug 30; 17(4):621-31. PubMed ID: 17882531
    [Abstract] [Full Text] [Related]

  • 7. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.
    Schödel F, Moriarty AM, Peterson DL, Zheng JA, Hughes JL, Will H, Leturcq DJ, McGee JS, Milich DR.
    J Virol; 1992 Jan 30; 66(1):106-14. PubMed ID: 1370083
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The immune response of rhesus macaques to novel vaccines comprising hepatitis B virus S, PreS1, and Core antigens.
    Chuai X, Xie B, Chen H, Tan X, Wang W, Huang B, Deng Y, Li W, Tan W.
    Vaccine; 2018 Jun 18; 36(26):3740-3746. PubMed ID: 29778513
    [Abstract] [Full Text] [Related]

  • 11. A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-specific T cells and preS1-specific antibodies.
    Malik IR, Chen A, Brass A, Ahlén G, Rahman M, Sällberg M, Qureshi JA, Frelin L.
    Scand J Infect Dis; 2012 Jan 18; 44(1):55-9. PubMed ID: 21933033
    [Abstract] [Full Text] [Related]

  • 12. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM, Chen S, Al-Mahtab M, Abe M, Hiasa Y, Onji M.
    Antiviral Res; 2012 Oct 18; 96(1):59-64. PubMed ID: 22884884
    [Abstract] [Full Text] [Related]

  • 13. A virulent Salmonella expressing hybrid hepatitis B virus core/pre-S genes for oral vaccination.
    Schödel F, Peterson D, Hughes J, Milich DR.
    Vaccine; 1993 Oct 18; 11(2):143-8. PubMed ID: 7679864
    [Abstract] [Full Text] [Related]

  • 14. Properties of modified hepatitis B virus surface antigen particles carrying preS epitopes.
    Prange R, Werr M, Birkner M, Hilfrich R, Streeck RE.
    J Gen Virol; 1995 Sep 18; 76 ( Pt 9)():2131-40. PubMed ID: 7561750
    [Abstract] [Full Text] [Related]

  • 15. Hepatitis B virus core-preS2 particles expressed by recombinant vaccinia virus.
    Nemecková S, Sroller V, Kunke D, Krystofová J, Kutinová L.
    Acta Virol; 1996 Sep 18; 40(5-6):273-9. PubMed ID: 9171455
    [Abstract] [Full Text] [Related]

  • 16. N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus.
    Bremer CM, Sominskaya I, Skrastina D, Pumpens P, El Wahed AA, Beutling U, Frank R, Fritz HJ, Hunsmann G, Gerlich WH, Glebe D.
    J Hepatol; 2011 Jul 18; 55(1):29-37. PubMed ID: 21145866
    [Abstract] [Full Text] [Related]

  • 17. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
    Li J, Ge J, Ren S, Zhou T, Sun Y, Sun H, Gu Y, Huang H, Xu Z, Chen X, Xu X, Zhuang X, Song C, Jia F, Xu A, Yin X, Du SX.
    Vaccine; 2015 Aug 20; 33(35):4247-54. PubMed ID: 25858855
    [Abstract] [Full Text] [Related]

  • 18. Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.
    Bian Y, Zhang Z, Sun Z, Zhao J, Zhu D, Wang Y, Fu S, Guo J, Liu L, Su L, Wang FS, Fu YX, Peng H.
    Hepatology; 2017 Oct 20; 66(4):1067-1082. PubMed ID: 28445927
    [Abstract] [Full Text] [Related]

  • 19. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
    Dai S, Zhuo M, Song L, Chen X, Yu Y, Zang G, Tang Z.
    Immunobiology; 2016 Jul 20; 221(7):813-21. PubMed ID: 26874581
    [Abstract] [Full Text] [Related]

  • 20. Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance.
    Whitacre DC, Peters CJ, Sureau C, Nio K, Li F, Su L, Jones JE, Isogawa M, Sallberg M, Frelin L, Peterson DL, Milich DR.
    Hum Vaccin Immunother; 2020 Jul 20; 16(2):251-268. PubMed ID: 31809638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.